Session » Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2757

A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing

9:00AM-11:00AM: Abstract Number: 2762

A Longer or Bilateral Temporal Artery Biopsy (TAB) Is More Likely to Yield a Positive Result for Giant Cell Arteritis (GCA) in the Veterans Health Administration (VHA) Database Cohort

9:00AM-11:00AM: Abstract Number: 2756

A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial

9:00AM-11:00AM: Abstract Number: 2769

A Single Center Experience of Temporal Artery Biopsies Performed in 30 African American Patients

9:00AM-11:00AM: Abstract Number: 2749

Clinical and Anatomical Correlation in Patients with Polymyalgia Rheumatica By 18F-FDG PET/TC. Study of 75 Patients from a Single Referral Center

9:00AM-11:00AM: Abstract Number: 2745

Clinical and Serological Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab or Abatacept As Steroid-Sparing Agents

9:00AM-11:00AM: Abstract Number: 2760

Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice

9:00AM-11:00AM: Abstract Number: 2768

Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study

9:00AM-11:00AM: Abstract Number: 2754

Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients

9:00AM-11:00AM: Abstract Number: 2771

Current Practice of Cardiovascular Risk Assessment in Giant Cell Arteritis: A Single Center Study

9:00AM-11:00AM: Abstract Number: 2773

Diagnostic and Therapeutic Management of a Suspected Case of GCA: An Opinion Survey

9:00AM-11:00AM: Abstract Number: 2777

Dynamics in Peripheral Blood Cell Counts in Giant Cell Arteritis before Treatment, during Treatment and in Treatment-Free Remission

9:00AM-11:00AM: Abstract Number: 2759

Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 2751

Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2783

EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases

9:00AM-11:00AM: Abstract Number: 2753

Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2748

Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT

9:00AM-11:00AM: Abstract Number: 2744

Giant-Cell Arteritis: Is Glucocorticoid-Sparing Treatment Still Relevant? a Retrospective Study

9:00AM-11:00AM: Abstract Number: 2767

Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 2778

High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 2761

High-Dose Prednisone Use up to 42 Days Prior to Temporal Artery Biopsy (TAB) Did Not Reduce Yield of Positive Biopsy in the Veterans Health Administration (VHA) Database Cohort

9:00AM-11:00AM: Abstract Number: 2772

Incidence of Cardiovascular Events in Giant Cell Arteritis: A Matched-Control Study

9:00AM-11:00AM: Abstract Number: 2764

Incidence, Characteristics and Management of Giant Cell Arteritis in France: A Study Based on National Health Insurance Claims Data

9:00AM-11:00AM: Abstract Number: 2780

Insufficient Use of Corticosteroids Results in Higher Relapse in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 2776

Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2782

Is It Necessary to Hold Anticoagulation Prior to Temporal Artery Biopsy?

9:00AM-11:00AM: Abstract Number: 2747

Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival

9:00AM-11:00AM: Abstract Number: 2781

Long Term Follow-up Results of Takayasu Arteritis Cohort: A Tertiary-Single Center Study

9:00AM-11:00AM: Abstract Number: 2779

Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 2784

Multi Modal Imaging Algorithm to Improve the Accuracy for the Diagnosis of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2775

Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2766

Seasonal Variation in Incidence of Giant Cell Arteritis: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 2770

The Effect of Metabolic Syndrome on Giant Cell Arteritis Treatment

9:00AM-11:00AM: Abstract Number: 2765

Thyroid Artery Involvement Detected By Colour-Doppler Ultrasonography in an Incipient, Single Centre Giant Cell Arteritis Cohort

9:00AM-11:00AM: Abstract Number: 2752

Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice

9:00AM-11:00AM: Abstract Number: 2758

Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study

9:00AM-11:00AM: Abstract Number: 2746

Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study

9:00AM-11:00AM: Abstract Number: 2774

Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice

9:00AM-11:00AM: Abstract Number: 2750

Utility of Methotrexate in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2763

Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2755

Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].